2023
Response to letter to the editor “noninvasive determinants of pulmonary hypertension in interstitial lung disease”
Joseph P, Savarimuthu S, Oakland H, Cullinan M, Heerdt P, Singh I. Response to letter to the editor “noninvasive determinants of pulmonary hypertension in interstitial lung disease”. Pulmonary Circulation 2023, 13: e12238. PMID: 37180828, PMCID: PMC10166920, DOI: 10.1002/pul2.12238.Peer-Reviewed Original Research
2019
MEF2 and the Right Ventricle: From Development to Disease
Clapham KR, Singh I, Capuano IS, Rajagopal S, Chun HJ. MEF2 and the Right Ventricle: From Development to Disease. Frontiers In Cardiovascular Medicine 2019, 6: 29. PMID: 30984767, PMCID: PMC6448530, DOI: 10.3389/fcvm.2019.00029.Peer-Reviewed Original ResearchPulmonary arterial hypertensionArterial hypertensionRight ventricleRight ventricular functionLife-limiting diseaseNovel therapeutic strategiesRight ventricular developmentEndothelial dysfunctionVentricular functionTherapeutic strategiesLeft ventricleHypertensionVentricleDisease statesVentricular developmentNormal physiologyMEF2 transcription factorsDiseaseAfterloadDysfunctionTranscription factors
2015
Pathophysiology of Pulmonary Hypertension in Chronic Parenchymal Lung Disease
Singh I, Cong K, Berlin DA. Pathophysiology of Pulmonary Hypertension in Chronic Parenchymal Lung Disease. The American Journal Of Medicine 2015, 129: 366-371. PMID: 26706386, DOI: 10.1016/j.amjmed.2015.11.026.Peer-Reviewed Original ResearchConceptsLung disease-associated pulmonary hypertensionChronic obstructive pulmonary diseaseObstructive pulmonary diseasePulmonary hypertensionLung diseasePulmonary diseaseChronic parenchymal lung diseaseNormal pulmonary circulationChronic lung diseaseIdiopathic pulmonary fibrosisInterstitial lung diseaseParenchymal lung diseasePulmonary fibrosisWorse prognosisPathophysiological factorsPulmonary circulationHypertensionDiseasePathophysiologyPhysiological determinantsSarcoidosisPrognosisFibrosis